Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes

• Published in: Frontiers in pharmacology Vol. 12; p. 634477
• Main Authors: Gasperetti, Tracy, Miller, Tessa, Gao, Feng, Narayanan, Jayashree, Jacobs, Elizabeth R, Szabo, Aniko, Cox, George N, Orschell, Christie M, Fish, Brian L, Medhora, Meetha
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 17-05-2021
• Subjects: acute radiation syndrome; delayed effects of acute radiation exposure; hematopoietic growth factor; lisinopril; mitigation; Pharmacology; polypharmacy; lisinopril; mitigation; hematopoietic growth factor; supportive care; delayed effects of acute radiation exposure; acute radiation syndrome; polypharmacy; radiation pneumonitis
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2021.634477

There is a need for countermeasures to mitigate lethal acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). In WAG/RijCmcr rats, ARS occurs by 30-days following total body irradiation (TBI), and manifests as potentially lethal gastrointestinal (GI) and hematopoietic (H-ARS) toxicities after >12.5 and >7 Gy, respectively. DEARE, which includes potentially lethal lung and kidney injuries, is observed after partial body irradiation >12.5 Gy, with one hind limb shielded (leg-out PBI). The goal of this study is to enhance survival from ARS and DEARE by polypharmacy, since no monotherapy has demonstrated efficacy to mitigate both sets of injuries. For mitigation of ARS following 7.5 Gy TBI, a combination of three hematopoietic growth factors (polyethylene glycol (PEG) human granulocyte colony-stimulating factor (hG-CSF), PEG murine granulocyte-macrophage-CSF (mGM-CSF), and PEG human Interleukin (hIL)-11), which have shown survival efficacy in murine models of H-ARS were tested. This triple combination (TC) enhanced survival by 30-days from ∼25% to >60%. The TC was then combined with proven medical countermeasures for GI-ARS and DEARE, namely enrofloxacin, saline and the angiotensin converting enzyme inhibitor, lisinopril. This combination of ARS and DEARE mitigators improved survival from GI-ARS, H-ARS, and DEARE after 7.5 Gy TBI or 13 Gy PBI. Circulating blood cell recovery as well as lung and kidney function were also improved by TC + lisinopril. Taken together these results demonstrate an efficacious polypharmacy to mitigate radiation-induced ARS and DEARE in rats.